Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

By Magnus Ingelman-Sundberg. The Pharmacogenomics Journal, 2005

1,126 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Oncology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/08bb204d64fdecff50a62580e91fef3026717266

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

1. Magnus Ingelman-Sundberg
2. Shufeng Zhou
3. M. Schwab
4. Ulrich M. Zanger
5. M. Eichelbaum
6. William E. Evans

In Oncology

1. Shufeng Zhou
2. Jun-Ping Liu
3. B. Chowbay
4. M. Schwab
5. Ulrich M. Zanger
6. M. Eichelbaum
7. William E. Evans
8. C. Rodríguez‐Antona

In Pharmacology

1. Shufeng Zhou
2. M. Eichelbaum
3. Jun-Ping Liu
4. B. Chowbay
5. M. Schwab
6. Magnus Ingelman-Sundberg
7. Ulrich M. Zanger
8. C. Rodríguez‐Antona

Citations in the corpus

• Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies (2007, background): “clinical practice (Smith et al., 1998, Ingelman-Sundberg, 2005).”
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “The molecular studies that followed were reviewed previously (Meyer & Zanger, 1997; Zanger et al., 2004; Ingelman-Sundberg, 2005).”
• Pharmacogenomics and individualized drug therapy. (2006, background): “Ultrarapid metabolizers (UMs) are preferentially distributed in the Mediterranean area, where 10% of the population in Portugal, Spain, and Italy carries alleles with multiple CYP2D6 gene copies (17, 46).”
• Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “The CNV in drugmetabolizing CYP have been suggested to be subjected to selection pressure to adapt to a changing dietary environment (Ingelman-Sundberg, 2005).”
• Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, background): “Although constituting only 2%–4% of the total amount of CYPs in the liver, CYP2D6 actively metabolizes approximately 20%–25% of all administered drugs [36].”
• Cytochrome P450 Enzymes and Drug Metabolism in Humans (2021, background): “CYP2D6, as the most common mutant isoform, is involved in the metabolic process of nearly 25% of clinical drugs, and its polymorphisms can affect the metabolic process of about 50% of these [51].”
• Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “CYP2D6 can metabolize a number of drugs that target the cardiovascular and central nervous system (>100) (Gardiner and Begg, 2006; Ingelman-Sundberg, 2005) and among these are many drugs with a narrow therapeutic index.”